Clinical Trials Logo
  1. Home
  2. Acute Graft Versus Host Disease
  3. NCT03557749

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Cytokine Release Syndrome Clinical Trial

Official title:
Monitoring of Immune and Microbial Reconstitution in Hematopoietic Cell Transplantation (HCT) and Novel Immunotherapies

Clinical Trial Summary

This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center in order to conduct correlative studies of the immune system, microbiota, and their interactions. Fluid (including but not limited to, blood, urine, saliva, cerebrospinal fluid, bronchoalveolar lavage fluid) sample log-in, processing, relabeling, and storage is performed by the Masonic Cancer Center (MCC) Translational Therapy Lab (TTL).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03557749
Study type Observational
Source Masonic Cancer Center, University of Minnesota
Contact
Status Terminated
Phase
Start date September 21, 2018
Completion date August 15, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Terminated NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04975555 - Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Phase 2
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT05349669 - Jafron Haemoadsorption During Cardiopulmonary Bypass Phase 2
Completed NCT04720378 - Safety and Tolerability Study of IV ST266 in COVID-19 Subjects Phase 1
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Completed NCT04403061 - Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Terminated NCT04377503 - Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Phase 2
Completed NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications Phase 2
Recruiting NCT04781803 - Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Phase 2
Completed NCT01353157 - Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Recruiting NCT04048434 - Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) N/A
Recruiting NCT04486521 - Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19